Genetic Analysis of Children with Congenital Ocular Anomalies in Three Ecological Regions of Nepal: A Phase II of Nepal Pediatric Ocular Diseases Study

CURRENT STATUS: Under Review

BMC Medical Genetics

Srijana Adhikari, Neelam Thakur, Ujjowala Shrestha, Mohan Shrestha, Murari Man Shrestha, Bijaya Thapa, Manish Poudel, Ajay Kunwar

Srijana Adhikari
Tilganga Institute of Ophthalmology

Corresponding Author
srij_a@yahoo.com

ORCID: https://orcid.org/0000-0003-4894-9533

Neelam Thakur
National Academic of Medical Sciences

Ujjowala Shrestha
Sudrishti Eye Centre

Mohan Shrestha
Tilganga Institute of Ophthalmology

Murari Man Shrestha
TUTH

Bijaya Thapa
Patan Academy of Health Sciences

Manish Poudel
Tilganga Institute of Ophthalmology

Ajay Kunwar
Kathmandu Centre for Genomics and research laboratory
Prescreen

10.21203/rs.3.rs-28804/v1

Subject Areas

Medical Genetics

Keywords

Nepal, pediatric, genetics, congenital anomalies, ocular
Abstract

Background: Genetic eye diseases constitute a large and heterogeneous group of childhood ocular morbidity. Individual diseases may cause multiple structural anomalies and developmental features. The Nepal Pediatric Ocular Disease Study (NPODS) was a population-based epidemiological study conducted across three ecological regions of Nepal to determine the prevalence and etiology of childhood ocular morbidity and blindness. In Phase II of this study, genetic analysis was performed for children who were found to have congenital ocular anomalies.

Methodology: It was a cross-sectional descriptive study. A total of 10,270 children across three different ecological regions in Nepal (terai, hills, and mountains) underwent ocular examinations. 374 (3.6%) of these children were found to have ocular abnormalities, 30 of whom were thought to be congenital in nature. Targeted genetic analysis, including genotyping for specific genes specific to the presenting phenotype, was performed for 25 children using serum samples.

Results: Out of 25 children, 18 children had meaningful genetic results. Analysis revealed one missense alteration G12411T of ZFHX4 gene in one participant among 10 with congenital ptosis and another missense variation T>C P.Y374C of STRA6 gene in one participant among 3 with microphthalmos.

Conclusion: The study is first of its kind from Nepal and mutant genes were unique to Nepalese Population. Further analysis of genetic factors is crucial to better understand genetic association with ocular diseases and conditions. This helps further in genetic counseling and probably gene therapy to prevent blindness from these conditions.

Background

Visual impairment is one of the most common disabilities affecting children. There is an estimated 1.4 million children worldwide who are blind, two-thirds of whom live in developing countries such as Nepal (1). Controlling childhood blindness has been a top priority of the World Health Organization since its launch of the VISION 2020: The Right to Sight global initiative in 1999 (2). Congenital ocular anomalies are one of the important causes of childhood ocular morbidity and blindness.) The genetic and hereditary eye diseases account for 11-39% of childhood blindness with more common in developed than in the developing world (3) Treatment is unfortunately often difficult or nonexistent for many of these congenital anomalies. Genetic testing in these situations can help to confirm diagnoses and thus provide prognostic information, guide interventions for the child, and assist in counseling regarding risk of disease occurrence in subsequent children. The Genetic Eye Disease Task Force of the American Academy of Ophthalmology has recommended various genetic testing of different congenital ocular anomalies (4)

Phase I of the Nepal Pediatric Ocular Disease Study (NPODS) determined the prevalence of childhood ocular morbidity and blindness across three ecological regions (lowlands, hills, mountains) of Nepal (5). Phase II of NPODS was the nested case control study to find out the risk factors of ocular morbidities identified in the first study (6). In this study, we conducted genetic analysis in children with congenital anomalies to understand the genetic implications of these diseases in Nepalese children.

Method

It was a cross-sectional descriptive study. Children identified as having congenital ocular anomalies in Phase 1 of NPODS were called for further genetic testing. Children aged 0 to 16 years were included. After getting pre informed written consent at the time of examination, the children’s parents were instructed to report to primary health center for blood sample collection. The genetic test was carried out in Kathmandu Centre for Genomics and Research Laboratory (KCGRL) in Kathmandu Nepal. A single 5 ml venous blood sample was collected from
each child while awake. DNA was extracted from the blood samples using a commercially-available DNA Extraction Kit (Qiagen; city, state) per the manufacturer’s protocol and evaluated for quality. Genotyping was done for a selected number of specific genes which corresponded to the presenting phenotype of each child. (Fig. 1) Locations of mutations were identified by conventional methods as well as reference Single Nucleotide Polymorphism (SNP) ID available. Genomic reference sequences spanning the mutation locus were downloaded from db SNP as well as Genbank database. Polymerase chain reaction primers to amplify these loci were designed using Primer design version 3 online tool. Primers were chosen such that they amplify 300–500 bp size amplicons and location of mutation is central to the amplicon where Sanger sequencing reads are having high QV bars. Furthermore, Primers were designed using Chromosomal DNA reference sequence, db SNP reference sequences and primer 3 design software available at bioinfo.ut.ee/primer3-0.4.0. to amplify each locus. (Table 1)

The Polymerase Chain Reaction (PCR) was carried out in a 25 µl volume with the final mix containing 10 x PCR buffer, 1.25 mM dNTPs, 25 mM MgCl₂, 10 pmole of each primer, 2.5 U of Taq polymerase and 2.5 µl of DNA template. The sample was heated to 95 °C for 5 min, followed by 35 cycles of 95 °C for 30 sec, 55 °C for 30 sec, 72 °C for 30 seconds and a final extension at 72 °C for 10 min. (Fig. 2)

| Disease Name       | Primer Name | Primer Sequence                                                                 | PCR Product |
|--------------------|-------------|---------------------------------------------------------------------------------|-------------|
| Congenital Ptosis  | ATPL_ZF2    | 5’TGTAGTGCAGCAACAGTTTGG 3’                                                       | 445         |
|                    | ATPL_ZF3    | 5’CATGGCAAGCAAAAAACAAAAAT 3’                                                     |             |
| Congenital Cataract| ATPL_GJ1    | 5’CTGCTGAGGACCTACATCTGC 3’                                                       | 405         |
|                    | ATPL_GJ2    | 5’CAAGGGGAATAGTGGAAC3’                                                           |             |
| Crouzen Syndrome   | ATPL_FG1    | 5’CAGCCAATAACCTGGGATGTA 3’                                                       | 458         |
|                    | ATPL_FG2    | 5’TCCCCACCCGGAACCTTGGA 3’                                                        |             |
| Crouzen Syndrome   | ATPL_FG3    | 5’GATCAAGCAGTGGAAGGAAGA 3’                                                        | 448         |
|                    | ATPL_FG4    | 5’AGCTCTTTCCATCCACTCCAT 3’                                                        |             |
| Microphthalmus     | ATPL_ST1    | 5’AGGTGGGCTCCATGACAG 3’                                                           | 380         |
|                    | ATPL_ST2    | 5’CATTTGGCATCATCTG 3’                                                            |             |
| Microphthalmus     | ATPL_ST3    | 5’TATTAGCCCCATTTTGCAATG 3’                                                        | 405         |
|                    | ATPL_ST4    | 5’GAGGTTAGTAGAGGGCAGCAT 3’                                                        |             |
|       | ATPL     | Primer Sequence                       | ATPL       |   |
|-------|----------|---------------------------------------|------------|---|
|       | CR1      | 5’ GCTCCTGGAGGAATCTGAGTT 3’           | OT1        | 317 |
|       | CR2      | 5’ AAAAGTCTCTAGCACCAGTCCTC 3’         | OT2        |    |
|       | OT1      | 5’ AGCCTCCCCAACTTTCTTACA 3’           | OT3        | 404 |
|       | OT2      | 5’ GAAGCTGGGCTCCAGATAGAC 3’           | OT4        |    |
|       | OT3      | 5’ TGAGACCTGGCCAAAAAGAAGA 3’          | AB1        | 387 |
|       | OT4      | 5’ AAGCTGGGGACTGATTGAGAT 3’           | AB2        |    |
|       | AB1      | 5’ CCTGAGTCCCTGCTTCTTCTT 3’           |            | 366 |
|       | AB2      | 5’ AACTTGATCCAGATGCCATT 3’            |            |    |

Through the confirmation from correct size of amplification, samples were further subjected to DNA sequencing. (Table 2). Cycle sequencing reaction for each sample was performed in 0.2 mL PCR tube. The reaction included Terminator Ready Reaction Mix (BigDye®) Terminator v3.1 Cycle Sequencing Kit, Applied Biosystems) (0.5 µL), BigDye® Sequencing Buffer (1.8 µL), One sequencing primer (3.2 pmol), and template DNA (2 µL) with Standard Milli Q (SMQ) water (4.7 µL) to make up the volume of 10.0 µL. For each sample two sequencing reactions were performed one using forward primer and other with reverse primer. The cycle sequencing protocol was as follows: Initial denaturation at 96 ºC for 1 min, followed by 25 cycles of 96ºC for 10 secs, annealing at 50 ºC for 5 sec, and elongation at 60 ºC for 4 minutes.
Table 2
Samples with further DNA sequencing

| Lane Number | Sample Number | Gene   | Mutation covered               |
|-------------|---------------|--------|--------------------------------|
| M           | 100–1000 bp ladder | -      | -                              |
| 1           | A             | ZFHX4  | G12411T L4137F                  |
| 2           | B             | GJA8_Cx50 | c.649G > A (Val196Met)         |
| 3           | F             | FGFR2  | S267P (T-C)                    |
| 3           | F             | FGFR2  | C278F (G-T)                    |
| 3           | F             | FGFR2  | Q289P (A-C)                    |
| 4           | F             | FGFR2  | C342S (G-C)                    |
| 4           | F             | FGFR2  | C342Y (G-A)                    |
| 4           | F             | FGFR2  | C342W (C-G)                    |
| 4           | F             | FGFR2  | A344A (G-A)                    |
| 4           | F             | FGFR2  | S347C (C-G)                    |
| 5           | D             | STRA6  | T > C P.Y374C                  |
| 6           | D             | STRA6  | A > T P.L152M                  |
| 7           | D             | CRYBA4 | C > T P.R25W                   |
| 8           | D             | OTX2   | p. Gln104 X                    |
| 8           | D             | OTX2   | p. Gln106 His                  |
| 9           | D             | OTX2   | p. Thr186 Fs < frame shift     |
| 10          | C             | ABCB6  | p. Ala 57 Thr G^A              |

A: Congenital Ptosis
B: Congenital Cataract
C: Colobama
D: Microphthalmus
F: Crouzen Syndrome
Data management and Analysis

Data were entered into the electronic database. The codes, recodes, consistency, outlines etc were assessed through the use of Microsoft Excel. Data analysis was done in Statistical Package for Social Science (SPSS) version16.

Results

In Phase 1 of NPODS, a total of 10,270 children, aged 0 to 16 years across three different ecological regions of Nepal underwent vision screening. Within this cohort, 5208 children (50.7%) were from terai, 3136 (30.5%) were from the hill, and 1926 (18.8%) were from the mountain region. Ocular abnormalities were present in 374 (3.6%) of all the children examined. The ocular abnormalities in 30 of these children were thought to be congenital in nature. Within this group, 17 children were from terai, 4 were from the hill region, and 4 were from the mountain region.

Among the 30 children thought to have congenital ocular anomalies, 19 (63.3%) were male and 11 (36.7%) were female. Fourteen (46.7%) of the children had congenital ptosis, 6 (20.0%) of the children had congenital cataract, 4 (13.3%) of the children had iris and chorioretinal coloboma, 3 (10.0%) of the children had microphthalmos, 1 (3.3%) had Nevus of Ota, 1 (3.3%) had proptosis secondary to Crouzon syndrome, and 1 (3.3%) had Retinal dystrophy. Table 3 shows the pattern of congenital ocular diseases across the three ecological regions. Most of the children with congenital anomalies were from the Terai region. The total morbidity was also high in terai region. Genetic analysis was carried out in 25 children. Five (16.7%) children were non-responders. The summary of different gene mutations has been shown in Table 4.

| Disease pattern            | Terai N(%) | Hills N(%) | Mountains N (%) | Total N (%) |
|----------------------------|------------|------------|-----------------|-------------|
| Coloboma                   | 4 (13.3)   | 0 (0)      | 0 (0)           | 4 (13.3)    |
| Congenital Ptosis          | 10 (33.3)  | 2 (6.6)    | 2 (6.6)         | 14 (46.7)   |
| Congenital cataract        | 3 (10)     | 3 (10)     | 1 (3.3)         | 6 (20)      |
| Microphthalmous            | 3 (10)     | 0          | 0               | 3 (10)      |
| Nevus of Ota               | 0          | 0          | 1(3.3)          | 1 (3.3)     |
| Proptosis ( Crouzen syndrome) | 0         | 1(3.3)     | 0               | 1(3.3)      |
| Retinal dystrophy          | 1(3.3)     | 0          | 0               | 1(3.3)      |
| Total                      |            |            |                 |             |

Table 4
The result summary of genetic analysis
| RN | SN | Gene   | Mutation          | BASE Call | Result                      |
|----|----|--------|-------------------|-----------|-----------------------------|
| 1  | A  | ZFHX4  | G12411T           | T         | G12411T detected            |
|    |    |        | L4137F            |           |                             |
| 2  | B  | GJA8   | c.649G            | G         | c.649G > A Not detected     |
|    |    | Cx 50  | > A (Val196Met)   |           |                             |
| 3  | F  | FGFR2  | S267P (T-C)       | T         | Not detected                |
| 3  | F  | FGFR2  | C278F (G-T)       | G         | Not detected                |
| 3  | F  | FGFR2  | Q289P (A-C)       | A         | Not detected                |
| 4  | F  | FGFR2  | C342S (G-C)       | -         | Not detected                |
| 4  | F  | FGFR2  | C342Y (G-A)       | -         | Not detected                |
| 4  | F  | FGFR2  | C342W (C-G)       | -         | Not detected                |
| 4  | F  | FGFR2  | A344A (G-A)       | -         | Not detected                |
| 4  | F  | FGFR2  | S347C (C-G)       | -         | Not detected                |
| 5  | D  | STRA6  | T > C             | C         | T > C p.Y374C detected      |
|    |    |        | p.Y374C           |           |                             |
| 6  | D  | STRA6  | A > T             | T         | L152L present, mutation not detected. |
|    |    |        | p.L152M           |           |                             |
| 7  | D  | CRYBA4 | C > T             | C         | Mutation not detected       |
|    |    |        | p.R25W            |           |                             |
| 8  | D  | OTX2   | p. Gln104 X       | C         | p. Gln104 X Not detected    |
|    |    |        |                   |           |                             |
### Discussion

In the current era of genetic advances, the diagnosis of genetic eye diseases is increasing and facilitated by collaborations between ophthalmologists and geneticists. Genetic testing can not only help confirm suspected diagnoses, but also provide important prognostic information and guide management for the individual affected but also help provide appropriate genetic counseling for parents. A comprehensive genetic evaluation requires a thorough clinical examination, a detailed family history, and access to advanced technology for molecular investigation.

We carried out the genetic analysis to find out molecular pattern and any significant mutations of inherited eye diseases in Nepalese children. In our study, congenital anomalies were most commonly present in terai region with 18 cases followed by 4 in mountains and 5 in hills. Five types of congenital anomalies were studied ie congenital ptosis, microphthalmos, congenital cataract, coloboma and Crouzon syndrome. Among these only crouzen syndrome was only found to be familial where mother was also affected.

Hereditary cataracts are clinically and genetically heterogeneous, often presenting as congenital or developmental cataracts that arises at birth or during the first few decades of life (7). Approximately 25% of non-syndromic cataracts are inherited (8). They can also be grouped into three major classes, based on the functions of known underlying genes, those that code for crystallins, membrane/cytoskeleton proteins, and transcription factors. At least 35 independent loci, including more than 20 known genes, have been identified for non-syndromic cataract (Cat-Map) (9,10). Mutations in crystallin genes account for the majority of missense mutations (nearly 50%) followed by mutations in the genes for cytosomeal or membrane proteins (nearly 35%) (9). The Gap Junction Protein Alpha 8 (GJA8) and Gap Junction Protein Alpha 3 (GJA3) mutations together account for 20% of the reported total non-syndromic familial cataracts worldwide (9). We selected a known SNP c.649G > A (Val196Met) from the same gene GJA8 and tested for the children with congenital cataract. This variation was not found in our patient with congenital cataract.

We selected one alteration in the ZFXH4 gene, G12411T in the children with congenital ptosis. This alteration was also previously reported in a Japanese family (11). This change was also detected in one child with congenital ptosis.

Another group of children were with iris and chorioretinal coloboma and microphthalmia. Microphthalmia and iris
and chorioretinal coloboma are related structural, congenital eye malformations which display a spectrum of severity and can occur in isolation or as part of a syndrome. Microphthalmia refers to a small eye, defined by axial length. Iris coloboma is a segmental ocular defect resembling a key hole deficiency in iris. Chorioretinal coloboma is associated with iris choloaboma and visually significant if posterior pole is involved. (12). The STRA6 gene plays a key role in normal ocular development, encoding a transmembrane receptor for the retinol-binding protein (RBP) and is responsible for mediating vitamin A uptake from circulation to target organs including the eye (13). We selected two SNP in STRA6 (T > C P. Y374C and A > T P. L152M) gene which are already found in database. We could identify one of these mutations in as well.

The second gene we have selected was Crystalline Beta A 4 (CRYBA4). It is known that complex microphthalmia in association with genetic cataracts has been attributed to mutations in the CRYBA4 gene (14). We selected one SNP C > T P.R25W from CRYBA4 gene which could not be identified in our patient.

The next gene is Orthodenticle Homeobox 2 (OTX2). The OTX2 gene encodes a transcription factor critical for forebrain and eye development (15). The OTX2 protein contains a homeodomain, responsible for DNA binding, SGQFTP and SIWSPA motifs involved in protein–protein interactions, and two C-terminal tandem OTX-tail motifs responsible for transactivation (16). We have selected three SNP p. Gln104 X, p. Gln106 His, p. Thr186 Fs < frame shift from OTX2 gene which could not be identified in our patient.

We have also selected one SNP p. Ala 57 Thr G/A from ATP Binding Cassette Sub Family B Member 6 (ABCB6) gene, which is involved in the active transport of various compounds vital for CNS development, but could not identify this mutation in our patient. Crouzen syndrome is an autosomal dominant craniosynostosis disorder that can be caused by mutation in the Fibroblast Growth Factor Receptor 2 (FGFR2) genes. (18) We also selected few SNP from FGFR2 gene, which codes for fibroblast growth factor receptor, which are mentioned in table for Crouzon syndrome but we were not able to find any mutation. (19). The limitation of our study was small sample size. Apart from the diseases included in the study, we could widen our research in other types of congenital ocular anomalies.

**Conclusion**

Our study was the first of its kind in Nepal to identify genetic mutations associated with congenital ocular anomalies. Through our analysis, two new mutations were identified in children with congenital ptosis and the microphthalmos unlike other studies on genetic analysis of congenital ptosis and microphthalmos.

**List Of Abbreviation**

NPODS (Nepal Pediatric Ocular Disease Study)

STRA6: Signaling Receptor and Transporter Retinol 6

ZFHX4: Zinc Finger Homeobox 4

KCGRL: Kathmandu Centre for Genomics and Research Laboratory

SNP: Single Neucleotide Polymorphism

PCR: Polymerase Chain Reaction

dNTPs: Deoxy Nucleotide Triphosphates

SMQ: Standard Milli Q

SPSS: Statistical Package for Social Science
GJA8: Gap Junction Protein Alfa 8
RBP: Retinol Binding Protein
CRYBA4: Crystallin Beta A 4
OTX2: Orthodenticle Homeobox 2
ABCB6 Gene: ATP binding Cassette Subfamily B Member 6
FGFR 2: Fibroblast Growth Factor Receptor 2

Declarations

Ethics approval and consent to participate
This study was approved by the Institutional Review Committee of the Tilganga Institute of Ophthalmology. The study adheres to the tenets of the Declaration of Helsinki. The written informed consent was obtained from a parent or guardian for participants under 16 years old.

Consent for publication
Not applicable

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interest
The authors declare that they have no competing interests.

Funding
The study was carried out by the research grant of Fred Hollows Foundation Australia.

Author’s contribution
All authors have read and approved the manuscript. Each author’s contribution in carrying out this research and writing the manuscript has been listed as follows
SA: Principal investigator of this research and wrote most parts of the manuscript
NT: Clinical genetic specialist helped in manuscript preparation and genetic analysis
US: Helped in manuscript preparation
MKS: Helped in manuscript preparation and study design
MMS: Helped in study design
MP: Helped in data analysis
BT: Helped in study design
AK: Helped in research design and genetic analysis
Acknowledgement: We Acknowledge the Fred Hollows Foundation for providing a research grant in support of this study. We acknowledge Dr. Sophia Fang, Pediatric Ophthalmologist from University of Utah for helping in grammar check and manuscript.

References

1. WHO. Program for the Prevention of Blindness and Deafness, Global initiative for the elimination of avoidable blindness. Geneva WHO; 2000.
2. WHO. Program for the Prevention of Blindness and Deafness, IAPB. Preventing blindness in children. report of WHO/IAPB scientific meeting. Geneva: WHO; 2000.
3. Gilbert C, Rahi J, Eckstein M, Foster A Mar;16(1):1-10 Hereditary disease as a cause of childhood blindness: regional variation. Results of blind school studies undertaken in countries of Latin America, Asia and Africa. Ophthalmic Genet. 1995.
4. The American Academy of Ophthalmology Task force. on Genetic testing Recommendation for genetic testing of inherited eye diseases. Guidelines of American Academy of ophthalmology, February 2014.
5. Adhikari S, Shrestha MK, Adhikari K, Maharjan N, Shrestha UD. Causes of visual impairment and blindness in children in three ecological regions of Nepal: Nepal Pediatric Ocular Diseases Study. Clin Ophthalmol. 2015 Aug 25;9:1543-7
6. Adhikari S, Shrestha U, Shrestha MK, Paudyal M, Thapa B, Shrestha M. Environmental factors associated with ocular morbidity among children in three ecological regions of Nepal: a phase II Nepal Pediatric Ocular Diseases Study Int Ophthalmol. 2017 Oct 14.
Figure 1

Agarose Gel electrophoresis A: Congenital Ptosis B: Congenital Cataract C: Colobama D: Microphthalmus, F: Crouzen Syndrome
Figure 2

Agarose Gel electrophoresis of PCR products on 2% (w/V) agarose gel
Shows sequence result of G12411TL4137F mutation in ZFHX4 gene in a child with congenital Ptosis
Figure 4

Showing T>C P. Y374C mutation in STRA6 gene in a child with microphthalmous

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- STROBEchecklistv4combined1.doc
- Thestrobestatementchecklistforgeneticsmanuscript.docx